This is a working overview of CJC-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-12 and is reviewed periodically as new material appears.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
When an employer requests a drug test from an employee, or a physician requests a drug test from a patient, the employee or patient is typically instructed to go to a collection site or their home. The urine sample goes through a specified 'chain of custody' to ensure that it is not tampered with or invalidated through lab or employee error. The patient or employee's urine is collected at a remote location in a specially designed secure cup, sealed with tamper-resistant tape, and sent to a testing laboratory to be screened for drugs (typically the Substance Abuse and Mental Health Services Administration 5 panel). The first step at the testing site is to split the urine into two aliquots. One aliquot is first screened for drugs using an analyzer that performs immunoassay as the initial screen. To ensure the specimen integrity and to detect possible adulterants, additional parameters are tested for. Some test the properties of normal urine, such as, urine creatinine, pH, and specific gravity. Others are intended to catch substances added to the urine to alter the test result, such as, oxidants (including bleach), nitrites, and gluteraldehyde. If the urine screen is positive then another aliquot of the sample is used to confirm the findings by gas chromatography—mass spectrometry (GC-MS) or liquid chromatography - mass spectrometry methodology. If requested by the physician or employer, certain drugs are screened for individually; these are generally drugs part of a chemical class that are, for one of many reasons, considered more habit-forming or of concern.
== Medical uses == Dofetilide is used for the maintenance of sinus rhythm in individuals prone to the occurrence of atrial fibrillation and flutter arrhythmias, and for chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. Based on the results of the Danish Investigations of Arrhythmias and Mortality on Dofetilide ("DIAMOND") study, dofetilide does not affect mortality in the treatment of patients post-myocardial infarction with left ventricular dysfunction, however it was shown to decrease all-cause readmissions as well as CHF-related readmissions. Because of the results of the DIAMOND study, some physicians use dofetilide in the suppression of atrial fibrillation in individuals with LV dysfunction, however use appears limited: After initially receiving marketing approval in Europe in 1999, Pfizer voluntarily withdrew this approval in 2004 for commercial reasons and it is not registered in other first world countries. It has clinical advantages over other class III antiarrhythmics in chemical cardioversion of atrial fibrillation, and maintenance of sinus rhythm, and does not have the pulmonary or hepatotoxicity of amiodarone, however atrial fibrillation is not generally considered life-threatening, and dofetilide causes an increased rate of potentially life-threatening arrhythmias in comparison to other therapies.
== Gameplay == The player controls the main character (Chell in both single player campaigns, or Atlas and P-Body in the Portal 2 co-op campaign) from a first-person view, running, jumping, and interacting with switches or other devices. The player-characters are able to withstand large drops, but can be killed by falling in the toxic water of the facility, crushed to death, passing through laser grids, or fired on repeatedly by turrets. Both games are generally divided into a series of test chambers; other sections of the game are more exploratory areas that connect these chambers. Each chamber has an exit door that must be reached, often requiring that certain conditions have been met such as having weighed down a large button with a "Weighted Cube", effectively a crate. These puzzles require the use of the Aperture Science Handheld Portal Device, the portal gun. The gun can be upgraded shoot two portals, colored differently for identification, on any flat surface that is painted with a specific paint containing moon dust. Once both portal ends are placed, the player can walk the character between them, or carry objects with the portal gun through them. Portal ends can be re positioned as often as necessary, but certain actions, such as walking through "emancipation grills" or moving a surface with a portal will cause the portals to dissipate.
== Evolutionary view == Multiple urocortin genes are present in vertebrate lineages as a result of the two waves of vertebrate whole-genome duplication. Two ligands, the CRF/UCN1 and UCN2/UCN3 paralogs, and two receptors, CRFR1 and CRFR2, were produced by a first genome duplication in early vertebrates. The CRF system observed in modern vertebrates, which has four ligands and two receptors, was then created by a second genome duplication that split the gene between UCN2 and UCN3 and between CRF and UCN1. Two peptide genes were hypothesized to have been present in a vertebrate progenitor that gave rise to the different lineages that contained urocortin (UCN I), CRH1, and CRH2 in one group and urocortin II (UCN II) and urocortin III (UCN III ) in the other. In many vertebrates, there are five members of the corticotropin-releasing hormone and urocortin family of peptides: CRH (crha/crhb in teleosts), CRH2, UCN/UTS1, UCN II, and UCN III. The two receptors, CRFR1 and CRFR2, and the four ligands, CRF, Urocortin1 (UCN1), UCN2, and UCN3, make up the mammalian CRF system. Genes for mentioned proteins can perform a multitude of tasks in a wide range of animals due to differences in their expression patterns and receptor affinities.
Holyhead Old Town is built around St Cybi's Church, which is built inside one of Europe's few three-walled Roman forts (the fourth boundary being the sea, which used to come up to the fort). The Romans also built a watchtower on the top of Holyhead Mountain inside Mynydd y Twr, a prehistoric hillfort. Settlements in the area date from prehistoric times, with circular huts, burial chambers and standing stones featuring in the highest concentration in Britain. The current lighthouse is on South Stack on the other side of Holyhead Mountain. Soldiers Point Hotel, located near the breakwater park in Holyhead, was built in 1848 as the residence of an engineer who was in charge of the government-sponsored alterations to Holyhead Harbour being carried out. It was badly damaged in a fire in 2011.
Sources: en.wikipedia.org
== History == Safrole was obtained from a number of plants, but especially from the sassafras tree (Sassafras albidum), which is native to North America, and from Japanese star anise (Illicium anisatum, called shikimi in Japan). In 1844, the French chemist Édouard Saint-Èvre (1817–1879) determined safrole's empirical formula. In 1869, the French chemists Édouard Grimaux (1835–1900) and J. Ruotte investigated and named safrole. They observed its reaction with bromine, suggesting the presence of an allyl group. By 1884, the German chemist Theodor Poleck (1821–1906) suggested that safrole was a derivative of benzene, to which two oxygen atoms were joined as epoxides (cyclic ethers). In 1885, the Dutch chemist Johann Frederik Eijkman (1851–1915) investigated shikimol, the essential oil that is obtained from Japanese star anise, and he found that, upon oxidation, shikimol formed piperonylic acid, whose basic structure had been determined in 1871 by the German chemist Wilhelm Rudolph Fittig (1835–1910) and his student, the American chemist Ira Remsen (1846–1927). Thus, Eijkman inferred the correct basic structure for shikimol. He also noted that shikimol and safrole had the same empirical formula and had other similar properties, and thus he suggested that they were probably identical. In 1886, Poleck showed that upon oxidation, safrole also formed piperonylic acid, and thus shikimol and safrole were indeed identical. It remained to be determined whether the molecule's C3H5 group was a propenyl group (R−CH=CH−CH3) or an allyl group (R−CH2−CH=CH2).
EF-G has a complex evolutionary history, with numerous paralogous versions of the factor present in bacteria, suggesting subfunctionalization of different EF-G variants. Elongation factors exist in all three domains of life with similar function on the ribosome. The eukaryotic and archeal homologs of EF-G are eEF2 and aEF2, respectively. In bacteria (and some archaea), the fusA gene that encodes EF-G is found within the conserved str gene with the sequence 5′ - rpsL - rpsG - fusA - tufA - 3′. However, two other major forms of EF-G exist in some species of Spirochaetota, Planctomycetota, and δ-Proteobacteria (which has since been split and renamed Bdellovibrionota, Myxococcota, and Thermodesulfobacteriota), which form the spd group of bacteria that have elongation factors spdEFG1 and spdEFG2. From spdEFG1 and spdEFG2 evolved the mitochondrial elongation factors mtEFG1 (GFM1) and mtEFG2 (GFM2), respectively. The two roles of EF-G in elongation and termination of protein translation are split amongst the mitochondrial elongation factors, with mtEFG1 responsible for translocation and mtEFG2 responsible for termination and ribosomal recycling with mitochondrial RRF.
== Taxonomy == The American black bear is not closely related to the brown bear or polar bear, though all three species are found in North America; genetic studies reveal that they split from a common ancestor 5.05 million years ago (mya). American and Asian black bears are considered sister taxa and are more closely related to each other than to the other modern species of bears.
== History == 1930s – first reports of the use of sucrose for gel electrophoresis; moving-boundary electrophoresis (Tiselius) 1950 – introduction of "zone electrophoresis" (Tiselius); paper electrophoresis 1955 – introduction of starch gels, mediocre separation (Smithies) 1959 – introduction of polyacrylamide gels; discontinuous electrophoresis (Ornstein and Davis); accurate control of parameters such as pore size and stability (Raymond and Weintraub) 1965 – introduction of free-flow electrophoresis (Hannig) 1966 – first use of agar gels 1969 – introduction of denaturing agents especially SDS separation of protein subunit (Weber and Osborn) 1970 – Lämmli separated 28 components of T4 phage using a stacking gel and SDS 1972 – agarose gels with ethidium bromide stain 1975 – 2-dimensional gels (O'Farrell); isoelectric focusing, then SDS gel electrophoresis 1977 – DNA sequencing gels (Sanger) 1981 – introduction of capillary electrophoresis (Jorgenson and Lukacs) 1984 – pulsed-field gel electrophoresis enables separation of large DNA molecules (Schwartz and Cantor) 2004 – introduction of a standardized polymerization time for acrylamide solutions to optimize gel properties with preparative native PAGE A 1959 book on electrophoresis by Milan Bier cites references from the 1800s. However, Oliver Smithies made significant contributions. Bier states: "The method of Smithies ... is finding wide application because of its unique separatory power." Taken in context, Bier clearly implies that Smithies' method is an improvement.
Sources: en.wikipedia.org
Norman architecture typically stands out as a new stage in the architectural history of the regions they subdued. They spread a unique Romanesque idiom to England, Italy and Ireland, and the encastellation of these regions with keeps in their north French style fundamentally altered the military landscape. Their style was characterised by rounded arches, particularly over windows and doorways, and massive proportions. In England, the period of Norman architecture immediately succeeds that of the Anglo-Saxon and precedes the Early Gothic. In southern Italy, the Normans incorporated elements of Islamic, Lombard, and Byzantine building techniques into their own, initiating a unique romanesque style known as Norman-Arab architecture within the Kingdom of Sicily and precedes the Early Gothic.
Group 1 are 'high affinity sulfate transporters', which are involved in the uptake of sulfate by the roots. Group 2 are vascular transporters and are 'low affinity sulfate transporters'. Group 3 is the so-called 'leaf group', however, still little is known about the characteristics of this group. Group 4 transporters are involved in the efflux of sulfate from the vacuoles, whereas the function of Group 5 sulfate transporters is not known yet, and likely function only as molybdate transporters. Regulation and expression of the majority of sulfate transporters are controlled by the sulfur nutritional status of the plants. Upon sulfate deprivation, the rapid decrease in root sulfate is regularly accompanied by a strongly enhanced expression of most sulfate transporter genes (up to 100-fold) accompanied by enhanced sulfate uptake capacity. It is not yet fully understood whether sulfate and other metabolic products of sulfur assimilation (O-acetylserine, cysteine, glutathione) act as signals in the regulation of sulfate uptake and transport, or in the expression of the sulfate transporters involved.
For example, the chemotherapeutic drugs oxaliplatin and cyclophosphamide can cause tumor cells to die in a way that is detectable by the immune system (called immunogenic cell death), which mobilizes immune cells with antitumor functions. Chemotherapeutic drugs that cause cancer immunogenic tumor cell death can make unresponsive tumors sensitive to immune checkpoint therapy.
{\displaystyle {\hat {H}}={\frac {{\hat {p}}_{x}^{2}+{\hat {p}}_{y}^{2}+{\hat {p}}_{z}^{2}}{2m}}+{\frac {\omega _{c}}{2}}({\hat {x}}{\hat {p}}_{y}-{\hat {y}}{\hat {p}}_{x})+{\frac {1}{2}}m\left({\frac {\omega _{1}}{2}}\right)^{2}({\hat {x}}^{2}+{\hat {y}}^{2})+{\frac {1}{2}}m\omega _{z}^{2}{\hat {z}}^{2}}
The absorption rate constant Ka is a value used in pharmacokinetics to describe the rate at which a drug enters into the system. It is expressed in units of time−1. The Ka is related to the absorption half-life (t1/2a) per the following equation: Ka = ln(2) / t1/2a. Ka values can typically only be found in research articles. This is in contrast to parameters like bioavailability and elimination half-life, which can often be found in drug and pharmacology handbooks.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.